# Study Evaluating Refacto For Pharmacovigilance

> **NCT00195442** · — · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 288 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **DRUG:** Moroctocog alfa

## Key facts

- **NCT ID:** NCT00195442
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 1999-07
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 288 (ACTUAL)
- **Last updated:** 2011-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00195442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00195442, "Study Evaluating Refacto For Pharmacovigilance". Retrieved via AI Analytics 2026-09-16 from https://api.ai-analytics.org/clinical/NCT00195442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*